about
Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsDepot-Based Delivery Systems for Pro-Angiogenic Peptides: A ReviewResistance to antibiotics targeted to the bacterial cell wallAntimicrobial Peptides Targeting Gram-Positive BacteriaInvestigations to the Antibacterial Mechanism of Action of KendomycinEfficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)Antibiotics in the clinical pipeline at the end of 2015.Vancomycin revisited - 60 years laterOritavancin for acute bacterial skin and skin structure infections.New antibiotic agents in the pipeline and how they can help overcome microbial resistance.Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.Advances in MRSA drug discovery: where are we and where do we need to be?Novel avenues for Clostridium difficile infection drug discovery.New antibiotics for bad bugs: where are we?Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Oritavancin: first global approval.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Novel antibiotics: are we still in the pre-post-antibiotic era?Oritavancin: A Long-Half-Life Lipoglycopeptide.Oritavancin: a review in acute bacterial skin and skin structure infections.New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.Oritavancin: a long-acting antibacterial lipoglycopeptide.Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.New agents approved for treatment of acute staphylococcal skin infectionsOritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant EnterococciNewer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: a systematic review, network meta-analysis and cost analysis.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.Harnessing the synthetic capabilities of glycopeptide antibiotic tailoring enzymes: characterization of the UK-68,597 biosynthetic cluster.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Developments in Glycopeptide Antibiotics.Single Intravenous Dose of Oritavancin for the Treatment of Gram-positive Acute Bacterial Skin and Skin Structure Infections: Summary of Safety from the Phase 3 SOLO studies.Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.
P2860
Q26799701-4FC14722-8003-4973-8B26-1097DDEE0025Q26799856-DD50BC91-B03B-4381-8A6E-76E4C2CD3C49Q26859841-8E25378C-38F1-4C6C-A811-42CEC2D07B36Q28077888-CC0CCB12-308E-4A04-83AF-4F26B33DDB91Q28552709-F9033BCB-491E-4F51-9F20-65E7B00EB17BQ28821040-F65A0679-C215-4A1F-B58D-CE5D4B7B4F7FQ30249262-5E385F03-84E3-41B1-9C2F-74CCA51B8964Q34433066-69F313A2-D5F6-4C9A-B1A4-3D8697649EEFQ36086423-E89B8043-0584-4DC1-98D7-EA95B8DA989EQ36845895-4DBC5293-AEE2-4C39-ADD4-4E9382DF1B7CQ36933484-9D30B572-F290-42D9-A4F8-B51BFED58AADQ37112508-7ED56032-07F6-44D0-B680-336A1FA8B4A8Q38083297-5BFEA567-B8F3-4DAD-A848-C52E8C3A9C67Q38132217-DFA93BA9-14ED-489D-9DB7-09FCD38C3C89Q38233471-C4232778-6B27-4115-88E0-95E2984CE346Q38242081-66ED7AC0-E9E2-4B0B-9E79-EE931B6DF644Q38252710-411E4876-EC24-41F8-933B-5D0582B761A1Q38347765-6A6F1CB1-F03A-4055-8284-9F109D8E1983Q38363223-310AC8BF-ED76-4D83-B178-167A3495854BQ38434265-B90BB674-77FE-428A-A6DE-059E41014C3EQ38606618-5515DBE6-5692-4DB5-A531-95969C3DEE37Q38768071-69ED4E79-B3C6-4998-BF71-5582135713AFQ38830176-EE925385-AA1F-451C-9B8A-F1BFC519F9E3Q38848903-8D31EF25-2E07-488F-9FBA-99317F48AD80Q39025172-273FBE64-63F5-4260-ABA6-79D20FF767D4Q39516822-0DA8108B-3E02-45A8-8F8D-5076B3C6D07AQ40052636-DE7390CF-D9EB-4B37-9CAA-28D1D9E9EC77Q41073732-0B80400C-907D-41BB-9D91-F218DA16069BQ41493636-588BA9F0-BCDA-4949-BD0E-AA401BD11240Q41726222-EFB5A886-E3A2-4845-98F9-FDE06E084398Q42530056-FF5B0B20-C569-41C4-930D-C69F594357A1Q47715119-1343BEFF-333E-445E-80F4-0F0CD45616E2Q49874661-FFC43954-3ACB-42EE-8EDF-D8A32BAA21F5Q52680606-902936BC-F329-4452-B670-6E54C1804A08
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Oritavancin: mechanism of action.
@ast
Oritavancin: mechanism of action.
@en
Oritavancin: mechanism of action.
@nl
type
label
Oritavancin: mechanism of action.
@ast
Oritavancin: mechanism of action.
@en
Oritavancin: mechanism of action.
@nl
prefLabel
Oritavancin: mechanism of action.
@ast
Oritavancin: mechanism of action.
@en
Oritavancin: mechanism of action.
@nl
P356
P1476
Oritavancin: mechanism of action.
@en
P2093
Frank Schweizer
James A Karlowsky
P304
P356
10.1093/CID/CIR920
P407
P478
54 Suppl 3
P577
2012-04-01T00:00:00Z